FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382751738> ?p ?o ?g. }

• W4382751738 endingPage "e006920" @default.
• W4382751738 startingPage "e006920" @default.
• W4382751738 abstract "Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but did elicit a longer duration of response and offered a favorable safety profile. This prespecified exploratory analysis was conducted to evaluate associations between tumor gene expression signatures and clinical outcomes in the phase III KEYNOTE-061 trial. Methods Using RNA sequencing data obtained from formalin-fixed, paraffin-embedded baseline tumor tissue samples, we evaluated the 18-gene T-cell-inflamed gene expression profile (Tcell inf GEP) and 10 non-Tcell inf GEP signatures (angiogenesis, glycolysis, granulocytic myeloid-derived suppressor cell (gMDSC), hypoxia, monocytic MDSC (mMDSC), MYC, proliferation, RAS, stroma/epithelial-to-mesenchymal transition/transforming growth factor-β, WNT). The association between each signature on a continuous scale and outcomes was analyzed using logistic (objective response rate (ORR)) and Cox proportional hazards regression (progression-free survival (PFS) and OS). One-sided (pembrolizumab) and two-sided (paclitaxel) p values were calculated for Tcell inf GEP (prespecified α=0.05) and the 10 non-Tcell inf GEP signatures (multiplicity-adjusted; prespecified α=0.10). Results RNA sequencing data were available for 137 patients in each treatment group. Tcell inf GEP was positively associated with ORR (p=0.041) and PFS (p=0.026) for pembrolizumab but not paclitaxel (p>0.05). The Tcell inf GEP-adjusted mMDSC signature was negatively associated with ORR (p=0.077), PFS (p=0.057), and OS (p=0.033) for pembrolizumab, while the Tcell inf GEP-adjusted glycolysis (p=0.018), MYC (p=0.057), and proliferation (p=0.002) signatures were negatively associated with OS for paclitaxel. Conclusions This exploratory analysis of tumor Tcell inf GEP showed associations with ORR and PFS for pembrolizumab but not for paclitaxel. Tcell inf GEP-adjusted mMDSC signature was negatively associated with ORR, PFS, and OS for pembrolizumab but not paclitaxel. These data suggest myeloid-driven suppression may play a role in resistance to PD-1 inhibition in G/GEJ cancer and support a strategy of considering immunotherapy combinations which target this myeloid axis. Trial registration number NCT02370498 ." @default.
• W4382751738 created "2023-07-01" @default.
• W4382751738 creator A5006249276 @default.
• W4382751738 creator A5010492722 @default.
• W4382751738 creator A5012380788 @default.
• W4382751738 creator A5014075249 @default.
• W4382751738 creator A5015799240 @default.
• W4382751738 creator A5018976795 @default.
• W4382751738 creator A5019473289 @default.
• W4382751738 creator A5019533297 @default.
• W4382751738 creator A5043091366 @default.
• W4382751738 creator A5045393539 @default.
• W4382751738 creator A5054654521 @default.
• W4382751738 creator A5059080863 @default.
• W4382751738 creator A5060841115 @default.
• W4382751738 creator A5065172378 @default.
• W4382751738 creator A5073330859 @default.
• W4382751738 creator A5074217604 @default.
• W4382751738 creator A5075464309 @default.
• W4382751738 creator A5085952795 @default.
• W4382751738 creator A5090832721 @default.
• W4382751738 date "2023-06-01" @default.
• W4382751738 modified "2023-10-15" @default.
• W4382751738 title "Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial" @default.
• W4382751738 cites W1999574084 @default.
• W4382751738 cites W2111237964 @default.
• W4382751738 cites W2158717244 @default.
• W4382751738 cites W2655262992 @default.
• W4382751738 cites W2782485041 @default.
• W4382751738 cites W2806614796 @default.
• W4382751738 cites W2884397450 @default.
• W4382751738 cites W2884883038 @default.
• W4382751738 cites W2888408613 @default.
• W4382751738 cites W2897815318 @default.
• W4382751738 cites W2900665741 @default.
• W4382751738 cites W2904444972 @default.
• W4382751738 cites W2946126594 @default.
• W4382751738 cites W2961644267 @default.
• W4382751738 cites W2977498449 @default.
• W4382751738 cites W2978609674 @default.
• W4382751738 cites W3112334180 @default.
• W4382751738 cites W3113663408 @default.
• W4382751738 cites W3128646645 @default.
• W4382751738 cites W3145734939 @default.
• W4382751738 cites W3165003875 @default.
• W4382751738 cites W3165648749 @default.
• W4382751738 cites W3197648443 @default.
• W4382751738 cites W4200186763 @default.
• W4382751738 cites W4205797333 @default.
• W4382751738 cites W4210362744 @default.
• W4382751738 cites W4214568242 @default.
• W4382751738 cites W4226216807 @default.
• W4382751738 cites W4286296240 @default.
• W4382751738 cites W4288734447 @default.
• W4382751738 doi "https://doi.org/10.1136/jitc-2023-006920" @default.
• W4382751738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37399357" @default.
• W4382751738 hasPublicationYear "2023" @default.
• W4382751738 type Work @default.
• W4382751738 citedByCount "2" @default.
• W4382751738 countsByYear W43827517382023 @default.
• W4382751738 crossrefType "journal-article" @default.
• W4382751738 hasAuthorship W4382751738A5006249276 @default.
• W4382751738 hasAuthorship W4382751738A5010492722 @default.
• W4382751738 hasAuthorship W4382751738A5012380788 @default.
• W4382751738 hasAuthorship W4382751738A5014075249 @default.
• W4382751738 hasAuthorship W4382751738A5015799240 @default.
• W4382751738 hasAuthorship W4382751738A5018976795 @default.
• W4382751738 hasAuthorship W4382751738A5019473289 @default.
• W4382751738 hasAuthorship W4382751738A5019533297 @default.
• W4382751738 hasAuthorship W4382751738A5043091366 @default.
• W4382751738 hasAuthorship W4382751738A5045393539 @default.
• W4382751738 hasAuthorship W4382751738A5054654521 @default.
• W4382751738 hasAuthorship W4382751738A5059080863 @default.
• W4382751738 hasAuthorship W4382751738A5060841115 @default.
• W4382751738 hasAuthorship W4382751738A5065172378 @default.
• W4382751738 hasAuthorship W4382751738A5073330859 @default.
• W4382751738 hasAuthorship W4382751738A5074217604 @default.
• W4382751738 hasAuthorship W4382751738A5075464309 @default.
• W4382751738 hasAuthorship W4382751738A5085952795 @default.
• W4382751738 hasAuthorship W4382751738A5090832721 @default.
• W4382751738 hasBestOaLocation W43827517381 @default.
• W4382751738 hasConcept C121608353 @default.
• W4382751738 hasConcept C126322002 @default.
• W4382751738 hasConcept C143998085 @default.
• W4382751738 hasConcept C2777701055 @default.
• W4382751738 hasConcept C2780057760 @default.
• W4382751738 hasConcept C2780739268 @default.
• W4382751738 hasConcept C3019894029 @default.
• W4382751738 hasConcept C502942594 @default.
• W4382751738 hasConcept C71924100 @default.
• W4382751738 hasConceptScore W4382751738C121608353 @default.
• W4382751738 hasConceptScore W4382751738C126322002 @default.
• W4382751738 hasConceptScore W4382751738C143998085 @default.
• W4382751738 hasConceptScore W4382751738C2777701055 @default.
• W4382751738 hasConceptScore W4382751738C2780057760 @default.
• W4382751738 hasConceptScore W4382751738C2780739268 @default.
• W4382751738 hasConceptScore W4382751738C3019894029 @default.
• W4382751738 hasConceptScore W4382751738C502942594 @default.

• next